Lytix Biopharma is pleased to announce that the study arm combining LTX-315 with pembrolizumab in patients with triple negative breast cancer now is completed. Due to the strong demand, the company decided to expand the enrolment in this trial arm. Seventeen patients received all planned injections of LTX-315 over 3 weeks. No clinically significant LTX-315 related adverse events or dose-limiting toxicities were observed.

Edwin Klumper, CEO of Lytix Biopharma, commented:

‘We are very pleased that recruitment in the triple negative breast cancer arm was strong. The combination therapy has shown to be a safe and feasible therapy for these patients. We eagerly await completion of this important clinical trial in the coming months to see the final readouts on clinical endpoints.”